Multiple Myeloma
What's New
Last Posted: Sep 18, 2023
- Targeted single-cell proteomic analysis identifies new liquid biopsy biomarkers associated with multiple myeloma
SM Setayesh et al, NPJ Prec Oncol September 18, 2023 - Artificial intelligence-enabled screening strategy for drug repurposing in monoclonal gammopathy of undetermined significance.
Alexander J Ryu et al. Blood cancer journal 2023 13(1) 28 - MGP Panel is a comprehensive targeted genomics panel for molecular profiling of multiple myeloma patients.
Sudha Parvathi et al. Clinical cancer research : an official journal of the American Association for Cancer Research 2022 - Comprehensive characterization of the epigenetic landscape in Multiple Myeloma.
Alaterre Elina et al. Theranostics 2022 12(4) 1715-1729 - Risk of multiple myeloma and other malignancies among first- and second-degree relatives of patients with multiple myeloma; A population-based study.
Langseth Øystein O et al. European journal of haematology 2022 - Impact of Omicron variant on the response to SARS-CoV-2 mRNA vaccination in multiple myeloma and monoclonal gammopathies
P Storti et al, MEDRXIV, February 26, 2022 - Machine Learning and Deep Learning Applications in Multiple Myeloma Diagnosis, Prognosis, and Treatment Selection.
Allegra Alessandro et al. Cancers 2022 14(3) - A polygenic risk score for multiple myeloma risk prediction.
Canzian Federico et al. European journal of human genetics : EJHG 2021 11 - High-Throughput Drug Screening and Multi-Omic Analysis to Guide Individualized Treatment for Multiple Myeloma.
Coffey David G et al. JCO precision oncology 2021 5 - Single-cell RNA sequencing: one step closer to the clinic- Single-cell RNA-sequencing can help in the prediction of drug resistance in patients with multiple myeloma
RS Pistofidis et al, Nature Medicine, March 4, 2021 - Q&A: John Carpten on the Genomics of Cancer Disparities.
et al. Cancer discovery 2020 Sep - Delineating the Complex Genomic Landscape of Multiple Myeloma Using Next-Generation Sequencing (NGS): Progress and Potential to Supersede Traditional Genetic Testing.
Garcia-Heras Jaime et al. Journal of the Association of Genetic Technologists 2020 46(3) 131-134 - Natural Language Processing of Serum Protein Electrophoresis Reports in the Veterans Affairs Health Care System.
Ryu Justine H et al. JCO clinical cancer informatics 2020 Aug 4749-756 - Clinical value of measurable residual disease testing for assessing depth, duration, and direction of response in multiple myeloma.
Martinez-Lopez Joaquin et al. Blood advances 2020 Jul 4(14) 3295-3301 - Utilization of CRISPR/Cas9 gene editing in cellular therapies for lymphoid malignancies.
Mehravar Maryam et al. Immunology letters 2020 Jul - Clinical utility of target capture-based panel sequencing in hematological malignancies: a multicenter feasibility study.
Yasuda Takahiko et al. Cancer science 2020 Jul - Hereditary Predisposition to Hematopoietic Neoplasms: When Bloodline Matters for Blood Cancers.
Mangaonkar Abhishek A et al. Mayo Clinic proceedings 2020 Jun - Next-Generation Sequencing for Clinical Management of Multiple Myeloma: Ready for Prime Time?
Bolli Niccolo et al. Frontiers in oncology 2020 10189 - Upgraded standardized minimal residual disease detection by next-generation sequencing in multiple myeloma.
Yao Qiumei et al. The Journal of molecular diagnostics : JMD 2020 Mar - Multiple Myeloma Genomics - A Concise Review.
Castaneda Omar et al. Acta medica academica 2019 Apr 48(1) 57-67 - Computational analysis of flow cytometry data in hematological malignancies: future clinical practice?
Duetz Carolien et al. Current opinion in oncology 2019 Dec - Prognostic model for multiple myeloma progression integrating gene expression and clinical features.
Sun Chen et al. GigaScience 2019 Dec 8(12) - Comprehensive detection of recurring genomic abnormalities: a targeted sequencing approach for multiple myeloma.
Yellapantula Venkata et al. Blood cancer journal 2019 Dec 9(12) 101 - Moving From Cancer Burden to Cancer Genomics for Smoldering Myeloma: A Review.
Maura Francesco et al. JAMA oncology 2019 Dec - CRISPR Approach To Fighting Cancer Called 'Promising' In 1st Safety Test
R Stein, NPR, November 6, 2019 - Crispr Takes Its First Steps in Editing Genes to Fight Cancer
D Grady, NY Times, November 6, 2019 - Doctors try CRISPR gene editing for cancer, a 1st in the US
M Marchione, Washington Post, November 6, 2019 - Toward personalized treatment in multiple myeloma based on molecular characteristics.
Pawlyn Charlotte et al. Blood 2019 133(7) 660-675 - European Myeloma Network recommendations on tools for the diagnosis and monitoring of multiple myeloma: what to use and when.
Caers Jo et al. Haematologica 2018 Nov 103(11) 1772-1784 - Family Members at Higher Risk for Blood Cancers
P Harrison, Medscape, September 9, 2019
More
About Rare Diseases PHGKB
Rare Disease PHGKB is an online, continuously updated, searchable database of published scientific literature, CDC and NIH resources, and other information that address the public health impact and translation of genomic and other precision health discoveries into improved health outcomes related to rare diseases...more
Content Summary
Selected Rare Diseases
- Alpha-1 Antitrypsin Deficiency
- Amyotrophic Lateral Sclerosis
- Brugada Syndrome
- Cerebral Palsy
- Cystic Fibrosis
- Duchenne Muscular Dystrophy
- Eclampsia
- Erythema Multiforme
- Familial Mediterranean Fever
- Fragile X Syndrome
- Gaucher Disease
- Glomerulonephritis
- Graves Disease
- Hemophilia
- Huntington Disease
- Microcephaly
- Myasthenia Gravis
- Phenylketonuria
- Retinitis Pigmentosa
- Severe Combined Immunodeficiency
Disclaimer: Articles listed in the Public Health Knowledge Base are selected by Public Health Genomics Branch to provide current awareness of the literature and news. Inclusion in the update does not necessarily represent the views of the Centers for Disease Control and Prevention nor does it imply endorsement of the article's methods or findings. CDC and DHHS assume no responsibility for the factual accuracy of the items presented. The selection, omission, or content of items does not imply any endorsement or other position taken by CDC or DHHS. Opinion, findings and conclusions expressed by the original authors of items included in the update, or persons quoted therein, are strictly their own and are in no way meant to represent the opinion or views of CDC or DHHS. References to publications, news sources, and non-CDC Websites are provided solely for informational purposes and do not imply endorsement by CDC or DHHS.
- Page last reviewed:Feb 1, 2024
- Content source: